Common Sense Oncology has developed principles designed to improve randomized phase 3 trials and ensure meaningful results. Recommendations address use of certain endpoints, toxicity reporting and ...

Bristol Myers (BMY) Squibb “announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos for the treatment of adult patients with symptomatic New York Heart Association class II-III non ...

After mass layoffs, the FDA has started missing certain deadlines, pushing one biopharma to delay a phase 3 trial and consider other paths to market, The Wall Street Journal reports. Women’s ...

Shortly after paying $800 million to take full control of BNT327, the biotech began a phase 3 trial to test the bispecific in combination with chemo in patients with previously untreated extensive ...

The U.S. Space Force has added Rocket Lab USA and Stoke Space to the National Security Space Launch, or NSSL, Phase 3 Lane 1 contract as part of the first on-ramp process for the launch services ...

Ironwood Pharmaceuticals shares sank after the company said it needs to conduct a confirmatory phase 3 trial of proposed short-bowel treatment apraglutide. The stock hit a 52-week low in mid ...

PHOENIX – The public is invited to celebrate the completion of Phase 3 of the Grand Canalscape improvement project in west Phoenix this weekend. The project transformed the dirt path along the ...

(RTTNews) - Eli Lilly and Company (LLY) Thursday reported topline data from Phase 3 ACHIEVE-1 study of orforglipron in adults with type 2 diabetes. The study met its primary goal. ACHIEVE-1 is the ...

Mark Huffman has been a consumer news reporter for ConsumerAffairs since 2004. He covers real estate, gas prices and the economy and has reported extensively on negative-option sales. He was ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa, which failed to show significant overall survival benefits in PROC. The trial's failure delays ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.